We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A short presentation

9 December 2003 By Robert Cyran

The US drugmaker has updated the market on its pipeline, and it is bare. With massive patent expirations around the corner, and little to replace them, Merck will be biding time for years.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)